Status:

Red

Decision Date:

August 2022

Comments

Treatment of adults with von Hippel-Lindau (VHL) disease. 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again